Subgroup interactions in the heart and estrogen/progestin replacement study: Lessons learned

Circulation

Volumn 105, Issue 8, 2002, Pages 917-922

  Furberg, Curt D ^a   Vittinghoff, Eric ^a   Davidson, Michael ^a   Herrington, David M ^a   Simon, Joel A ^a   Wenger, Nanette K ^a   Hulley, Stephen ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary disease; Hormones; Trials; Women

Indexed keywords

DIGITALIS; ESTROGEN; GESTAGEN; LIPOPROTEIN A; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CORONARY DISEASE; DATA INTERPRETATION, STATISTICAL; DEMOGRAPHY; DIGITALIS; DISEASE PROGRESSION; DRUG INTERACTIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; LIPOPROTEIN(A); MEDROXYPROGESTERONE 17-ACETATE; PARITY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037176920     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0802.104280     Document Type: Article

References (14)

1. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack trial experience
2. Heart and Estrogen/Progestin Replacement Study (HERS): Design, methods and baseline characteristics
3. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
4. Hormone replacement therapy, heart disease, and other considerations
5. Postmenopausal hormone-replacement therapy
6. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
7. Clinical judgment and statistics: Lessons from a simulated randomized trial in coronary artery disease
8. Effect of risk status on treatment criteria: Implications of hypertension trials
9. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel
10. Production of C-reactive protein and risk of coronary events in stable and unstable angina
11. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
12. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
13. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women